BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
97.69
+0.18 (+0.18%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close97.51
Open98.30
Bid95.69 x 1100
Ask99.99 x 1800
Day's Range95.64 - 98.46
52 Week Range75.81 - 106.74
Volume1,287,484
Avg. Volume997,280
Market Cap17.395B
Beta (3Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateFeb 20, 2019 - Feb 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est120.30
Trade prices are not sourced from all markets
  • 6 Stocks Beating the Market
    GuruFocus.com5 days ago

    6 Stocks Beating the Market

    According to the GuruFocus All-in-One Guru Screener, the following stocks have outperformed the Standard & Poor's 500 index over the past 12 months and were bought by gurus during the third quarter. Warning! GuruFocus has detected 6 Warning Signs with BGNE. The share price is 50.86% above its 52-week low and 34.65% below its 52-week high.

  • This is how much Apple pays a typical employee — and how that compares to Google, Facebook, Netflix, Microsoft, Box and more
    American City Business Journals7 days ago

    This is how much Apple pays a typical employee — and how that compares to Google, Facebook, Netflix, Microsoft, Box and more

    Apple's typical employee probably makes far less than you think: $55,426 per year. For comparison, the median employee at social media giant Facebook makes more than $240,000 per year. Most likely, that median employee at Apple is not somebody writing code or designing iPhones out of a cubicle in Cupertino, but rather a worker at one of the company's retail stores.

  • Is BioMarin Pharmaceutical Stock a Bargain?
    Motley Fool8 days ago

    Is BioMarin Pharmaceutical Stock a Bargain?

    BioMarin's shares stumbled in December, but better days appear to be ahead.

  • InvestorPlace11 days ago

    Why Sarepta Therapeutics Stock Is Starting to Shine Again

    Sarepta Therapeutics (NASDAQ:SRPT) started 2019 with very high volatility. After spiking to around $125 a share on Jan. 7, SRPT stock gave up those gains when markets took in the developments in its DMD pipelines and its Exondys 51 fourth-quarter sales outlook. Although shares rebounded from December 2018 lows, should biotech stock investors seriously consider investing in this company? At the J.P. Morgan conference, Sarepta said it will run 45 biopsies this quarter for SRP-4045. This is an investigational compound that treats DMD or Duchenne muscular dystrophy patients with mutations in the DMD gene. The drug works by directing cells, through Sarepta's PMO, to skip exon 45 when processing RNA. The dystrophin protein is shortened but is still synthesized, slowing the negative symptoms of DMD. If the biopsies are positive, Sarepta will file a marketing application, setting up a possible approval date of early 2020. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### SRPT's Sales Outlook SRPT stock volatility rose after the company issued its revenue outlook for Exondys 51. In the fourth quarter ended Dec. 31, 2018, it made $84.4 million in revenue from sales of Exondys 51. For 2018, revenue was around $301 million. It ended that same period with a healthy balance of $1.1 billion in cash. * 10 Key Emerging-Market Stocks to Buy for Contrarian Investors Markets reacted negatively to the outlook because it expected quarterly revenue of $85.8 million. The barely $2 million difference is a rounding error and the market quickly realized it. Quarterly revenue is in line with forecasts. As markets rebounded, taking the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) up 11.5% on the week, SRPT stock also rose the same amount (11%). Sarepta's global growth plans should lower the risks of relying solely in one market: "We continue to build our international presence with limited infrastructure but dedicated colleagues in Latin America and Europe and a managed access program or MAP now live in some 44 countries. We should continue to see modest contribution from our MAP throughout 2018 with increasing contribution in 2019 and beyond." Source: SA Transcript ### Impressive Talent at Sarepta Sarepta highlighted the 25 programs in RNA and gene therapy underway. Its staff talent consists of over 500 professionals. This leading gene therapy team could deliver on bringing 3 RNA-therapies by 2020. It may potentially treat 30% of the DMD market. Historically, the team is showing that it is delivering. FY 2018 revenue nearly doubled to $301 million, up from the 2017 revenue of $154.6 million. ### Investing Opportunity Sarepta is a top five rare disease company by market cap. Only Alexion Pharmaceuticals (NASDAQ:ALXN), BioMarin Pharmaceutical (NASDAQ:BMRN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are bigger. SRPT stock is underperforming compared to its peers. While the other firms' stock price traded closer to its 52-week highs after the market rally in the last few days, Sarepta is still around 33% below its yearly high. Wall Street coverage gained steam in the last few days. The company received over five "buy" calls, with a price target ranging from $161 to as high as $267. Analyst Firm Position Price Target Date Debjit Chattopadhyay H.C. Wainwright Buy $267.00 yesterday Salveen Richter Goldman Sachs Buy $191.00 2 days ago Matthew Harrison Morgan Stanley Buy $161.00 2 days ago Brian Skorney Robert W. Baird Buy $202.00 2 days ago Alethia Young Cantor Fitzgerald Buy $217.00 2 days ago Yun Zhong Janney Montgomery Buy $200.00 2 days ago Brian Abrahams RBC Capital Buy -- 3 days ago Martin Auster Credit Suisse Buy $189.00 3 days ago Tim Chiang BTIG Buy $190.00 13 days ago Source: tipranks ### Investment Suitability Like with all biotech companies in the discovery phase, SRPT is volatile and risky. Any FDA approval delays could disappoint markets, sending the stock lower. Clinical study costs could rise, but in Sarepta's case, the company has plenty of cash on hand. It is unlikely to need a cash raise through a share sale. * 7 Stocks to Buy That Are Run By Billionaires ### Bottom Line on SRPT Stock Sarepta Therapeutics stock benefited from the latest rebound in biotechnology stocks, but could move even higher in the longer term. It has a goal of commencing its confirmatory trial with commercial material this year. Given the strong team, doctors and scientists involved, chances are good that the trial, which has 24 patients, goes well and will bring positive results. As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post Why Sarepta Therapeutics Stock Is Starting to Shine Again appeared first on InvestorPlace.

  • 5 Biotech Stocks That Could Face M&A Next!
    InvestorPlace12 days ago

    5 Biotech Stocks That Could Face M&A Next!

    Biotech stocks are already making some big waves this year. That's because M&A activity is already surging. Drawn by some big-time values, some of the world's biggest pharmaceutical firms have gone shopping for beaten-down biotech bargains. Already, we've seen Bristol-Meyers (NYSE:BMY) score Celgene (NASDAQ:CELG) for a cool $74 billion in a game-changing acquisition. More recently, Eli Lilly (NYSE:LLY) announced that it was pushing harder into cancer treatments with an $8 billion offer for Loxo Oncology (NASDAQ:LOXO). The question on everyone's minds is "who is next?" InvestorPlace - Stock Market News, Stock Advice & Trading Tips With plenty of biotech stocks still trading for peanuts and coffers overflowing at the major pharma's, more M&A activity is guaranteed. And while betting on a buyout may be a fool's errand, there are plenty of biotech stocks out there are on my best stocks to invest in list anyway. A buyout would be icing on the cake. * Morgan Stanley: 7 Risky Stocks to Sell Now But which ones have the potential to snagged up because they are so good? Here are five biotech stocks that could be buy-out candidates. Source: Shutterstock ### Seattle Genetics (SGEN) With oncology and cancer on the minds of many of the biggest names pharma, biotech stock Seattle Genetics (NASDAQ:SGEN) could once again be in play. SGEN has one drug available for patients -- Adcetris -- which is used to treat Stage III/IV classical Hodgkin lymphoma. Sales of Adcetris continue to grow rapidly. In the last reported quarter, revenues for the drug jumped by over 60% year-over-year. Even better is that number of indications, combinations and other uses for Adcetris have grown like weeds. SGEN continue to rack up more approvals and "breakthrough" designations for the drug. All of this has only made the medicine more lucrative for the biotech stock. As if that wasn't enough for big pharma to be salivating at the firm, Seattle Genetics has been able to pivot its technology towards other forms of cancer. The firm has numerous drugs targeting urothelial, cervical, breast and multiple myeloma cancer varieties. Here again, SGEN has been quite successful in moving its drugs through the FDA's hoops. Given growing sales of Adcetris and its heavy-duty cancer-focused pipeline, any biopharma looking to make a splash in oncology would seriously be considering SGEN stock. With a market cap of just over $11 billion, Seattle Genetics could one of the next biotech stocks to be bought out. Source: Shutterstock ### Agios Pharmaceuticals (AGIO) Keeping with the cancer buy-out theme, Agios Pharmaceuticals (NASDAQ:AGIO) makes an intriguing biotech buyout candidate. AGIO has two cancer therapies on the market. Its latest, Tibsovo, has been approved for those acute myeloid leukemia patients with an IDH1 mutation. The other -- Idhifa -- is for acute myeloid leukemia patients who also test positive for an IDH2 mutation. The firm basically has a one-two punch for this specific variety of leukemia. And while the drugs are new, prescriptions are growing, with Tibsovo seeing a 100% quarter-over-quarter increase in its short life span. That makes it a buyout candidate alone. Tibsovo is wholly owned by Agios. However, the real kicker is that Idhifa came via a partnership with Celgene. Celgene -- soon to be Bristol Meyers -- must continue to pay royalties on sales from the drug via a tiered structure that gets into the mid-teens. Given its buyout of CELG, BMY may just want to control the whole pie, and with AGIO's market cap sitting at just over $3 billion, it's an easy pill to swallow. And with the two medicines, BMY would be getting a healthy pipeline of additional cancer therapies as well as some rare disease work for a song. * 10 Stocks You Can Set and Forget (Even In This Market) Given that, there's a good chance that AGIO gets the nod. No wonder why shares have jumped higher since both CELG's and LOXO's buyout bids. Source: Shutterstock ### Jazz Pharmaceuticals (JAZZ) It's very rare to find biotech stocks trading for bargain-basement valuations. But that's just what is happening at Jazz Pharmaceuticals (NASDAQ:JAZZ). Today, you can snag JAZZ stock for forward P/E of under 10. JAZZ has five drugs on the market, with narcolepsy drug Xyrem being a blockbuster. Sales of Xyrem continue to grow and are expected to surpass $1.4 billion this year. At the same time, its portfolio of hematology/oncology drugs are proven to be winners as well and are helping JAZZ realize a double-digit EPS growth rate. Acute myeloid leukemia treatment Vyxeos, which only launched last year, is set to pull in roughly $100 million in sales for the full year 2018 and more than $200 million this year. Adding to this is JAZZ's pending March approval for its new drug covering excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Another late-stage candidate for cataplexy in narcolepsy should hit regulatory approval at the end of the year. With a rich drug portfolio and pipeline, JAZZ is a rarity among biotech stocks. It's profitable -- so much so that the firm has authorized a $400 million buyback program. That's after it already repurchased over $600 million in shares. Analysts estimate that a dividend could even be coming next. Featuring a market cap of less than $8 billion, JAZZ would be an easy and profitable tuck-in for almost any big pharma stock. Source: Shutterstock ### Neurocrine Biosciences (NBIX) A rare miss for Neurocrine Biosciences (NASDAQ:NBIX) sent shares crashing this year and left the firm with a $7.5 billion market cap. But NBIX's pain could end up being AbbVie's (NASDAQ:ABBV) gain. Over the summer, NBIX and ABBV received an FDA approval for their drug Orilissa, which is used in the treatment of pain associated with endometriosis. The drug is currently wrapping up trials for the treatment of uterine fibroids. Analysts think the drug has blockbuster potential with annual sales of around $1 billion. On its own, NBIX has a blockbuster in Ingrezza. The drug is used to treat tardive dyskinesia -- which is marked by jerky movements of the face and body out of a patient's control. The problem is tardive dyskinesia is a side effect of many depression, schizophrenia and other mental health drugs. This is a huge market, and Ingrezza sales are taking off. Management at Neurocrine estimates that they'll be able to pull in over $400 million in Ingrezza sales in 2018. And NBIX has a full pipeline of other drugs in various stages of trials. With a buyout, ABBV gets full access to Orilissa without royalty and milestone fees for future indications. Secondly, Ingrezza is quickly becoming a major money marker for NBIX. That would fill a nice hole in AbbVie's revenue stream and would help pay for the deal over the long haul. * The 7 Best Stocks in the Entrepreneur Index All in all, given its low market cap, hefty cash balance and marketed drugs, AbbVie may end up swallowing NBIX whole. Source: Shutterstock ### BioMarin Pharmaceutical (BMRN) When politicians and pundits often talk about the high price of drugs and mention therapies costing more than $400,000 per year, odds are, they are talking about rare and orphan diseases. For biotech stocks, targeting these diseases -- which sometimes can affect very small population sizes -- it can mean plenty of long-term revenues down the road. Given the research required to crack these afflictions, the high drug prices are more than justified. BioMarin (NASDAQ:BMRN) is one biotech stock that has made rare diseases its specialty. The firm has seven drugs on the market targeting illnesses such as phenylketonuria and Batten disease. Rare disease medications come with longer exclusivity rights and by focusing here, BMRN basically ensures patient protection versus generic competition. At the same time, these drugs pull in some big-time revenues. For example, this year, BioMarin expects to make more than $1.5 billion in sales with its top five drugs. Meanwhile, the biotech stocks pipeline is rich as well with drugs for hemophilia and sanfilippo in late-stage trials. Because of its focus, profitability and rich rare disease pipeline, BioMarin has long been considered a buy candidate. With big pharma finally starting to spend some dough, that takeover may finally happen. At the time of writing, Aaron Levitt had a long position in CELG and JAZZ ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 5 Biotech Stocks That Could Face M&A Next! appeared first on InvestorPlace.

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    # Biomarin Pharmaceutical Inc ### NASDAQ/NGS:BMRN View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding BMRN are favorable, with net inflows of $11.31 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Benzinga13 days ago

    The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 8) Innoviva Inc (NASDAQ: INVA ) Organogenesis Holdings Inc ...

  • A Look at Sarepta Therapeutics’ Recent Developments
    Market Realist15 days ago

    A Look at Sarepta Therapeutics’ Recent Developments

    Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Earnings trends In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year. In the third quarter of 2018, the company reported net income and EPS of -$76.4 million and -$1.15, respectively, compared to -$47.7 million and -$0.78 in the third quarter of 2017. Wall Street analysts anticipate that in the fourth quarter of 2018, Sarepta Therapeutics will report net income and EPS of -$63.26 million and -$0.95, respectively. Analysts also estimate that the company will report net income and EPS of -$274.73 million and -$4.16, respectively, in fiscal 2018. Wall Street analysts estimate that BioMarin Pharmaceuticals (BMRN), Nektar Therapeutics (NKTR), and Vertex Pharmaceuticals (VRTX), Sarepta Therapeutics’ peers in the biopharmaceuticals market, will report EPS of around -$0.62, $3.88, and $2.88, respectively, in fiscal 2018. ## Recent developments On January 2, 2019, Sarepta Therapeutics entered a long-term strategic relationship with Aldevron. Aldevron is one of the leading producers of custom proteins, nucleic acids, and antibodies for use in the biotech industry. As per the terms of the agreement, Aldevron will supply plasmid DNA for the fulfillment of Sarepta Therapeutics’ requirements in its gene therapy clinical trials and commercial purposes. Aldevron will specifically supply GMP-grade plasmid for Sarepta Therapeutics’ micro-dystrophin Duchenne muscular dystrophy (or DMD) and Limb-girdle muscular dystrophy (or LGMD) gene therapy programs. As per the terms of the agreement, Aldevron will also supply plasmid for Sarepta Therapeutics’ future gene therapy programs. The agreement is expected to help Sarepta Therapeutics with sufficient plasmid for research and commercial purposes. Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 2 - How Is Sarepta Therapeutics Positioned in January?

  • How Is Sarepta Therapeutics Positioned in January?
    Market Realist15 days ago

    How Is Sarepta Therapeutics Positioned in January?

    Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million. In the third quarter of 2018, the company’s revenue grew ~71% YoY to $78.5 million from $46.0 million. Wall Street analysts estimate that Sarepta Therapeutics will generate revenues of $85.8 million in the fourth quarter of 2018. Analysts also estimate that the company’s net revenue in fiscal 2018 will be around $301.1 million, which represents ~49.9% YoY growth. In the third quarter of 2018, Nektar Therapeutics (NKTR), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN), Sarepta Therapeutics’ peers in the biopharmaceuticals market, reported revenues of $27.8 million, $783.9 million, and $391.7 million, respectively, which represents a ~81.9% YoY decline, a ~42.04% YoY increase, and a ~17.23% YoY increase. Wall Street analysts estimate that Nektar Therapeutics (NKTR), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN) will generate revenues of $1.2 billion, $3.0 billion, and $1.5 billion, respectively, which represents ~289%, ~37.41%, and ~15% YoY growth. ## Expense trends In the first nine months of 2018, Sarepta Therapeutics’ cost of sales excluding amortization of in-licensed rights amounted to $21.1 million compared to $3.8 million in the same period the prior year. In the first nine months of 2018, Sarepta Therapeutics reported R&D (research and development) and SG&A (selling, general, and administrative) expenses of $255.6 million and $143.5 million, respectively, compared to $122.3 million and $90.5 million in the same period the prior year. Wall Street analysts estimate that Sarepta Therapeutics will report cost of sales, SG&A, and R&D expenses of $30.2 million, $190.88 million and $317.02 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 3 - A Look at Sarepta Therapeutics’ Recent Developments

  • Sarepta Therapeutics Stock Rose 96% in 2018
    Market Realist15 days ago

    Sarepta Therapeutics Stock Rose 96% in 2018

    Who Is Eyeing Sarepta Therapeutics Now? ## Stock performance On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its close of $106.67 on January 3. Sarepta Therapeutics stock grew from $55.64 at the close of market on December 29, 2017, to reach $109.13 at the close of market on December 31, 2018, which represents ~96% growth over 2018. On January 2, 2019, Sarepta Therapeutics stock closed at $107.50, which is ~35% below its 52-week high of $176.50 on June 19, 2018. The company hit its 52-week low of $26.26 on February 13, 2018. ## Recent developments In December 2018, Sarepta Therapeutics (SRPT) completed the submission of its continuing NDA (new drug application) that seeks approval of its golodirsen for the treatment of individuals with Duchenne muscular dystrophy with genetic mutations associated to skipping exon 53 Duchenne gene. Sarepta Therapeutics’ golodirsen is an engineered phosphorodiamidate morpholino oligomer for the treatment of DMD with genetic mutations of skipping exon 53 of the DMD gene. ## Analyst recommendations Of the 24 analysts tracking Sarepta Therapeutics in January 2019, nine of them recommended a “strong buy,” while 14 analysts recommended a “buy” rating. One analyst recommended a “hold” for Sarepta Therapeutics in January. On January 7, Sarepta Therapeutics had a consensus 12-month target price of $194.36, which represents a ~68.38% return on investment over the next 12-months. ## Peers’ ratings In January 2018, of 27 analysts tracking BioMarin Pharmaceuticals (BMRN), ~78% of them recommended “buys.” Of the 11 analysts tracking Exelixis (EXEL), ~73% of them recommended “buys.” Of the 11 analysts tracking Nektar Therapeutics (NKTR), ~82% of them recommended “buys.” On January 7, BioMarin Pharmaceuticals (BMRN), Exelixis (EXEL), and Nektar Therapeutics (NKTR) had a consensus 12-month target price of $120.3, $28.78, and $78.89, respectively, which represents ~38.12%, ~38.83%, and a ~132.30% return on investment over the next 12 months. Continue to Next Part Browse this series on Market Realist: * Part 2 - How Is Sarepta Therapeutics Positioned in January? * Part 3 - A Look at Sarepta Therapeutics’ Recent Developments

  • PR Newswire15 days ago

    BioMarin Highlights Key Milestones for 2019 at 37th Annual J.P. Morgan Healthcare Conference in San Francisco

    During the company's presentation at the conference, Bienaimé provided information on the company's development program for valoctocogene roxaparvovec gene therapy for severe hemophilia A.  BioMarin has completed enrollment of the initial cohort of patients in its Phase 3 program intended to support a BLA submission through the accelerated approval pathway.  A decision to submit a BLA through an accelerated approval pathway is tracking for the second half of 2019.  If the company submits a BLA using the accelerated approval pathway, it will disclose additional information on the timing of its plans regarding the BLA submission.  The complete Phase 3 study is targeting enrollment of 130 patients by mid-year 2019. Valoctocogene roxaparvovec has Orphan Drug designation from the FDA and the European Medicines Agency (EMA).  Valoctocogene roxaparvovec has also been accepted for Priority Medicines (PRIME) scheme from the EMA.  Additionally, the FDA has granted valoctocogene roxaparvovec Breakthrough Therapy designation.

  • Outlook For Battered Biotech Stocks In 2019
    Investopedia16 days ago

    Outlook For Battered Biotech Stocks In 2019

    Biotech stocks, which have fallen 20% from last year's high based on the iShares Nasdaq Biotechnology ETF (IBB), could face more declines in the year ahead. A combination of negative headwinds including weak sales growth, earnings revisions and other forces are likely to plague the once-red hot sector.

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markit28 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Analyzing Sarepta Therapeutics’ Gross Margin Trends
    Market Realistlast month

    Analyzing Sarepta Therapeutics’ Gross Margin Trends

    In the third quarter, Sarepta’s (SRPT) cost of sales excluding the amortization of in-licensed rights rose YoY (year-over-year) to $8.74 million from $3.08 million.

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Sage Therapeutics: Analyzing New Product Candidates
    Market Realistlast month

    Sage Therapeutics: Analyzing New Product Candidates

    Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical company that focuses on developing treatments for central nervous system disorders. In this series, we’ll explore Sage Therapeutics’ financials, valuation, and analysts’ views on the stock.

  • Sage Therapeutics’ Operational Performance
    Market Realistlast month

    Sage Therapeutics’ Operational Performance

    In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively. The company’s revenues are expected to increase to $156.84 million in fiscal 2020. Biogen (BIIB), BioMarin Pharmaceutical (BMRN), and Sarepta Therapeutics (SRPT) are expected to have revenues of $13.31 billion, $1.52 billion, and $301.13 million, respectively, in fiscal 2018.

  • Sage Therapeutics: Do Analysts See Any Upside?
    Market Realistlast month

    Sage Therapeutics: Do Analysts See Any Upside?

    In the third quarter, Sage Therapeutics’ (SAGE) net interest income was $5.82 million—compared to $677,000 during the same period in 2017.

  • Benzingalast month

    Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved

    Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks. One factor that worked in ...

  • PR Newswirelast month

    BioMarin to Present at 37th Annual J.P. Morgan Healthcare Conference in San Francisco

    SAN RAFAEL, Calif. , Dec. 18, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will participate in the ...

  • Argentiere Capital’s Returns, AUM and Holdings
    Insider Monkeylast month

    Argentiere Capital’s Returns, AUM and Holdings

    Deepak Gulati‘s Argentiere Capital is a Zug, Switzerland-based hedge fund launched back in June 2013, with an additional office in Chicago. The fund is focused on offering its services to pooled investment vehicles and manages separate client-focused equity portfolios. It’s run by a team of former members of JP Morgan’s Global Equities Proprietary Trading Group […]

  • Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay
    American City Business Journalslast month

    Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay

    Orchard Therapeutics is tackling "bubble baby" disease and other rare genetic conditions with gene therapy.

  • Why Neurocrine Biosciences Stock Is Plummeting Today
    Market Realistlast month

    Why Neurocrine Biosciences Stock Is Plummeting Today

    Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11. Neurocrine stock has hit its 52-week low of $64.72. Neurocrine stock was trading at $103.0 at the close of market on November 12, and it reached $85.69 on December 11, representing a ~17% fall in the month.

  • Simply Wall St.last month

    Is BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) CEO Paid Enough Relative To Peers?

    Jean-Jacques Bienaimé has been the CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) since 2005. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at other big Read More...

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN